SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptor family ERRalpha, ERRbeta, and ERRgamma, with strong activity reported at ERRalpha. Although frequently marketed alongside peptides in research catalogs, it is not a peptide and should be classified accurately as a small-molecule research compound.

ERRs are orphan nuclear receptors involved in transcriptional control of mitochondrial function, oxidative metabolism, and muscle energy programs. Published studies have used SLU-PP-332 as a chemical probe to activate ERR-regulated pathways in cell systems and animal models. Preclinical work has reported changes in mitochondrial respiration, oxidative muscle-fiber programs, fatty-acid metabolism, energy expenditure, and exercise-associated gene expression.

The compound is best positioned for research on nuclear receptors, cellular bioenergetics, muscle physiology, and metabolic signaling. Findings to date are predominantly preclinical .  

Research Mechanism and Scientific Rationale

SLU-PP-332 functions as a pan-ERR agonist. By binding ERR nuclear receptors, it can promote transcription of genes involved in mitochondrial oxidative capacity, fatty-acid utilization, and aerobic energy metabolism. Experimental evidence indicates that ERRalpha is important for several observed effects, including induction of an acute aerobic-exercise-like gene program in skeletal muscle models.

This mechanism makes SLU-PP-332 useful for target-validation experiments, receptor-subtype comparisons, transcriptional profiling, mitochondrial assays, and evaluation of metabolic phenotypes. Study design should account for its reported limited oral bioavailability and for the distinction between cell-based activity and in vivo exposure.

Importance in Biological and Chemical Research

SLU-PP-332 provides researchers with a rare pharmacological tool for activating all three ERR subtypes, especially ERRalpha. It helps bridge nuclear-receptor pharmacology, mitochondrial biology, and whole-body metabolism while supporting the development of improved ERR-targeting compounds.

• 
  
• 
  

• Key Research Applications

  ERR Nuclear-Receptor Research

  Suitable for receptor activation assays, reporter-gene studies, subtype selectivity work, and target-validation experiments.

  Mitochondrial Function and Cellular Respiration

  Used to explore mitochondrial energy metabolism, mitochondrial content, cellular respiration responses, and bioenergetic regulation.

  Skeletal-Muscle Metabolism Research

  Supports studies of oxidative fiber programs, aerobic gene expression, substrate use, and muscle metabolic adaptation.

  Fatty-Acid Oxidation and Energy Expenditure Models

  Applied in preclinical metabolic research examining lipid utilization, energy balance, and associated transcriptional pathways.

  Medicinal Chemistry and Analog Development

  Useful as a reference compound for structure-activity studies and for designing next-generation ERR agonists with improved potency or exposure.

Why Choose Our SLU-PP-332?

· Correctly classified small-molecule ERR research agonist with a defined chemical identity.

· Suitable for biochemical, cell-based, transcriptional, and preclinical research workflows.

· Lot-specific identity, purity, and analytical documentation available according to the ordered grade.

· Controlled synthesis and impurity monitoring to support reproducible experimental work.

· Flexible supply for screening, reference-standard use, and medicinal-chemistry programs.